Royalty Pharma Q3 2026 attributable net income falls 49% year over year to $145 million
RPRX•Royalty Pharma’s third-quarter 2026 net income attributable to shareholders fell 49% year over year to $145 million, while total income and other revenues rose 13% to $690 million. The company recorded a $150 million noncash impairment related to pelacarsen after its Phase 3 trial failed to meet the primary endpoint.
1. Quarterly results
Royalty Pharma’s third-quarter 2026 net income attributable to shareholders fell 49% year over year to $145 million. Total income and other revenues rose 13% to $690 million. The company recorded a $150 million noncash impairment charge related to pelacarsen after its Phase 3 trial failed to meet the primary endpoint.
2. Royalty acquisition
In September, Royalty Pharma paid $100 million upfront to acquire a royalty interest in Zoryve from AstraZeneca.
